Table I.

Frequency and severity of arthritis in different mouse strains and following different depletion proceduresa

Group of MiceInjected AgentNo. of Mice, nFrequency of ArthritisSeverity Grade, Mean ± SD
NMRIPoly(IC)149/14b0.9 ± 0.9
NMRIPoly(I)144/140.5 ± 0.8
NMRIPBS141/140.1 ± 0.4
SCID (CB17)Poly(IC)74/70.6 ± 0.5
Non-SCID (CB17)Poly(IC)95/90.9 ± 0.8
IL-IR−/− (C57BL/6)Poly(IC)91/90.1 ± 0.3
IL-IR+/+ (C57BL/6)Poly(IC)105/100.5 ± 0.5
C3H/HeJPoly(IC)92/90.2 ± 0.4
C3H/HeNPoly(IC)92/90.2 ± 0.4
Etoposide (BALB/c)Poly(IC)92/90.3 ± 0.7
RB6–8C5 (BALB/c)Poly(IC)96/91.2 ± 0.4
Control IgG + PBSPoly(IC)95/91.0 ± 0.8
Etoposide (BALB/c) + RB6–8C5 (BALB/c)Poly(IC)103/100.4 ± 0.7
  • a Mice were killed 3 days after a single intra-articular injection with 20 μl of dsRNA (poly(IC); 10 μg/knee), ssRNA (poly(I), 10 μg/knee), and PBS (20 μl/knee). BALB/c mice were injected with etoposide (12.5 mg/kg, in a volume of 125 μl, s.c. into the groin) or PBS as a control on 3 consecutive days before and after intra-articula injection of dsRNA. BALB/c mice were injected i.p. with 1 mg of mAb RB6–8C5, or the IgG rat anti-OVA mAb as a control 2 hs prior to intra-articular injection with dsRNA.

  • b Value of p < 0.05, as compared with mice injected with PBS.